ArticleJCI insight2016
Systems biology analysis reveals role of MDM2 in diabetic nephropathy.
Open access · goldAbstract read
In one paragraph
Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 46 citations in OpenAlex.
- Role of the MDM2/p53 axis in regulating cisplatin response in tumor cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Liver-specific delivery of MDM2 antisense oligonucleotides counteracts diet-induced metabolic-dysfunction-associated steatotic liver diseases.Molecular therapy. Nucleic acids · 2026Article
- Formononetin inhibits p53 signaling pathway activation to delay cellular senescence and ameliorates diabetic kidney disease.World journal of diabetes · 2026Article
- New Insights into the Role of Mitochondrial Dysfunction in Diabetic Kidney Disease in the Omics Era.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Interconnected Mechanistic Pathways, Molecular Biomarkers, and Therapeutic Approach of Oral Cancer in Patients with Diabetes Mellitus.Current issues in molecular biology · 2025Review
- Diagnostic value of the correlation between urinary MDM2 and podocyte mitotic catastrophe in diabetic kidney disease.Diabetology & metabolic syndrome · 2025Article
- Elevation of p53 sensitizes obese kidney to adriamycin-induced aberrant lipid homeostasis via repressing HNF4α-mediated FGF21 sensitivity.Journal of advanced research · 2025Article
- The Impact of METTL3 on MDM2 Promotes Podocytes Injury During Diabetic Kidney Disease.Journal of cellular and molecular medicine · 2025Article
- Quinolinic acid potentially links kidney injury to brain toxicity.JCI insight · 2025Article
- Ursolic Acid Alleviates Mitotic Catastrophe in Podocyte by Inhibiting Autophagic P62 Accumulation in Diabetic Nephropathy.International journal of biological sciences · 2024Article
- New Approaches Targeting the Renin-Angiotensin System: Inhibition of Brain Aminopeptidase A, ACE2 Ubiquitination, and Angiotensinogen.The Canadian journal of cardiology · 2023Review
- MDM2 Influences ACE2 Stability and SARS-CoV-2 Uptake.Viruses · 2023Article
- p53 and Myofibroblast Apoptosis in Organ Fibrosis.International journal of molecular sciences · 2023Review
- Nanocurcumin combined with insulin alleviates diabetic kidney disease through P38/P53 signaling axis.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- SUPPRESION OF MITOCHONDRIAL RESPIRATION IS A FEATURE OF CELLULAR GLUCOSE TOXICITY.Transactions of the American Clinical and Climatological Association · 2023Article
- Emerging role of tumor suppressor p53 in acute and chronic kidney diseases.Cellular and molecular life sciences : CMLS · 2022Review
- Biofluid Specificity of Long Non-Coding RNA Profile in Hypertension: Relevance of Exosomal Fraction.International journal of molecular sciences · 2022Article
- Harnessing Metabolomics to Describe the Pathophysiology Underlying Progression in Diabetic Kidney Disease.Current diabetes reports · 2021Review
- Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators.Frontiers in pharmacology · 2021Article
- Targeted Next-Generation Sequencing Identifies Pathogenic Variants in Diabetic Kidney Disease.American journal of nephrology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 2 countries.
Rintaro SaitoInstitute of Metabolomic Medicine.
Anaïs Rocanin-ArjoMedizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU Munich, Munich, Germany.
Young-Hyun YouCenter for Renal Translational Medicine, Division of Nephrology-Hypertension.
Manjula DarshiInstitute of Metabolomic Medicine.
Benjamin Van EspenInstitute of Metabolomic Medicine.
Satoshi MiyamotoCenter for Renal Translational Medicine, Division of Nephrology-Hypertension.
Jessica PhamCenter for Renal Translational Medicine, Division of Nephrology-Hypertension.
Minya PuInstitute of Metabolomic Medicine.
Simone RomoliMedizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU Munich, Munich, Germany.
Loki NatarajanInstitute of Metabolomic Medicine.
Wenjun JuDepartment of Internal Medicine, Nephrology and Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.
Matthias KretzlerDepartment of Internal Medicine, Nephrology and Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.
Robert NelsonNational Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, USA.
Keiichiro OnoDivision of Medical Genetics, Department of Medicine, UCSD, San Diego, California, USA.
Dana ThomasovaMedizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU Munich, Munich, Germany.
Shrikant R MulayMedizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU Munich, Munich, Germany.
Trey IdekerDivision of Medical Genetics, Department of Medicine, UCSD, San Diego, California, USA.
Vivette D'AgatiRenal Pathology Laboratory, Columbia University, College of Physicians and Surgeons, Department of Pathology, New York, New York, USA.
Ergin BeyretSalk Institute for Biological Studies, San Diego, California, USA.
Juan Carlos Izpisua BelmonteSalk Institute for Biological Studies, San Diego, California, USA.
Hans Joachim AndersMedizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU Munich, Munich, Germany.
Kumar SharmaInstitute of Metabolomic Medicine.
Center for Translational Molecular Medicine · NLSalk Institute for Biological Studies · USNational Institute of Diabetes and Digestive and Kidney Diseases · US
Funding
SYNTHETIC SYSTEMSP50GM085764 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HASTY, JEFF M, IDEKER, TREY · 2010 to 2018
$23.3MTR&D 3 - Network Guided Machine LearningP41GM103504 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2012 to 2024
$17.3MUniversity of Michigan O'Brien Kidney Translational Core CenterP30DK081943 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KRETZLER, MATTHIAS · 2008 to 2022
$12.9MEpidemiology, Pathophysiology and Treatment of Diabetic NephropathyZIADK069062 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI NELSON, ROBERT G · 2009 to 2023
$10.1MNovel Paradigms in Diabetic ComplicationsDP3DK094352 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHARMA, KUMAR · 2011 to 2011
$6.0MAdiponectin and PodocytesI01BX000277 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI SHARMA, KUMAR · 2009 to 2013
–BLRD VA I01 BX000277NIDDK NIH HHS DP3 DK094352NIDDK NIH HHS P30 DK081943NIGMS NIH HHS P41 GM103504NIGMS NIH HHS P50 GM085764
Abstract
To derive new insights in diabetic complications, we integrated publicly available human protein-protein interaction (PPI) networks with global metabolic networks using metabolomic data from patients with diabetic nephropathy. We focused on the participating proteins in the network that were computationally predicted to connect the urine metabolites.
Indexed as
Systems BiologyAlbuminuriaAnimalsComputational BiologyDiabetes Mellitus, ExperimentalDiabetic NephropathiesHumansKidney GlomerulusKidney TubulesMiceMice, Inbred C57BLMice, KnockoutPodocytesProto-Oncogene Proteins c-mdm2MDM2 protein, humanProto-Oncogene Proteins c-mdm2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.